Shannon M. Patrick
Associate
Experience
Successfully represented Bausch & Lomb and Eye Therapies in a Hatch-Waxman patent infringement litigation and parallel PTAB challenges concerning an ANDA for generic versions of over-the-counter Lumify® ocular drops. The cases settled favorably for our clients.
3:21-cv-16766, D.N.J., Judges Kirsch, Singh
IPR2022-00146, PTAB, Judges Hulse, New, Pollock
IPR2024-00467, PTAB, Judges Flax, Pollock, Yang
IPR2022-00142, PTAB, Judges Flax, Hulse, New, Pollock
Incyte Corporation et al. v. Sun Pharmaceutical Industries Limited et al.
Successfully represented Incyte in patent litigation, including preliminary injunction proceedings related to Sun Pharmaceuticals’ deuterated Janus kinase (JAK) inhibitor, LEQSELVI™. Case settled favorably for our client.
2:24-cv-06944, D.N.J., Judge Padin
AbbVie Inc., et al. v. Aurobindo Pharma U.S.A., Inc. et al.
Finnegan is representing AbbVie, Allergan, and Merck in ongoing ANDA litigation involving Ubrelvy®, indicated for the acute treatment of migraine with or without aura in adults.
3:24-cv-04603, D.N.J., Judges Quraishi, Day
3:24-cv-04662, D.N.J., Judges Quraishi, Day
3:24-cv-04852, D.N.J., Judges Quraishi, Day
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
Successfully defended Novartis against Genzyme’s multiple patent infringement actions and inter partes review (IPR) proceedings related to recombinant adeno-associated virus vector technology used in Novartis’ blockbuster, breakthrough gene therapy Zolgensma®. The case settled after four patents were invalidated during claim construction, five patents found not literally infringed, and institution of multiple IPRs.
1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews
01-19-0001-6937; 01-20-0000-5081, AAA
Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al.
Trial counsel for Novartis in district court litigation against multiple generics related to KISQALI ®, a blockbuster, breakthrough CDK4/6-inhibitor for the treatment of breast cancer. After a bench trial, the case resulted in a favorable settlement for our client, supporting patent protection at least until 2031.
1:21-cv-00870, D. Del., Judge Hall
Insights
At the PTAB Blog
Claim Construction Leads to Unpatentability for Lack of Written Description Support
September 20, 2023
At the PTAB Blog
“Nearly All” Not Quite Good Enough to Achieve Discretionary Denial Under §325(d)
September 8, 2023
News
Professional Activities
- Order of the Coif
Admissions
- U.S. Patent and Trademark Office
- Georgia
- U.S. Court of Appeals, Veterans Claims
Education
- Emory University School of Law
- J.D., with high honors, 2020
- University of Georgia
- B.S., Biology, cum laude, 2017
- University of Georgia
- B.A., Political Science, cum laude, 2017
Shannon's Practices
- Global IP Enforcement, Litigation, and Trials
- Branded Hatch-Waxman (ANDA) Litigation and Trials
- Patent Litigation and Trials
- Pretrial Strategies
- Trademark Litigation and Trials
- Patent Office Invalidation Proceedings
- Ex Parte Reexamination (EPR)
- PTAB Invalidation Proceedings: IPR and PGR
- Prosecution and Portfolio Management
- Ex Parte Reexamination (EPR)
- IP Portfolio Management
- Licensing, Pooling, and Other Transactions
- Opinions and Counseling
- Patent Drafting and Prosecution
- Trademark Counseling and Prosecution
Shannon's Industries
- AI, Electronics, and Information Technology
- Electrical and Computer Technology
- Electronic Devices and Components
- Chemicals, Industrials, and Materials
- Chemical
- Manufacturing
- Consumer Goods and Services
- Food and Beverage
- Hospitality, Gaming, and Leisure
- Sports, Fitness, and Outdoor Recreation
- Life Sciences
- Biologics
- Biotechnology
- Medical Device and Diagnostics
- Pharmaceutical
- Transportation and Logistics
- Automotive and Smart Mobility Tech